H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Amarin (AMRN – Research Report) today and set a price target of $3.00. The company's shares closed last Thursday at $1.28, close to its 52-week low of $1.11. According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.2% and a 37.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. Amarin has an analyst consensus of Hold, with a price target consensus of $2.80, a 124.0% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-hold-on-amarin-amrn?utm_source=advfn.com&utm_medium=referral
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Amarin Charts.
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Amarin Charts.